In one paragraphArticle in Science translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
17 authors.
Nina B HorowitzDepartment of Otolaryngology-Head & Neck Surgery, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-5151-7945 Imran A MohammadDepartment of Otolaryngology-Head & Neck Surgery, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0003-2288-2887 June Ho ShinDepartment of Otolaryngology-Head & Neck Surgery, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0001-9278-1331 Peter ChockleyPelotonia Institute for Immuno-Oncology, Ohio State University Comprehensive Cancer Center-the James, Columbus, OH 43210, USA.ORCID 0000-0002-5181-2696 Gail SnyderDepartment of Otolaryngology-Head & Neck Surgery, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Chen ChenDepartment of Otolaryngology-Head & Neck Surgery, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.
Keene LeeDepartment of Otolaryngology-Head & Neck Surgery, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0003-1780-8893 Krishna SharmaDepartment of Otolaryngology-Head & Neck Surgery, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0009-0006-1300-8871 Quan TranDepartment of Otolaryngology-Head & Neck Surgery, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-5769-3480 Sainiteesh MaddineniDepartment of Otolaryngology-Head & Neck Surgery, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0003-4152-273X Vasu DiviDepartment of Otolaryngology-Head & Neck Surgery, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-6219-6294 Catherine A BlishDivision of Infectious Diseases, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0001-6946-7627 Garry P NolanDepartment of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-8862-9043 Jennifer A FoltzSection of Computational Biology, Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0001-9158-3464 John B SunwooDepartment of Otolaryngology-Head & Neck Surgery, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-8393-4196 Funding
Reprogramming the Tumor-Immune Interface in Oral CancerR35DE030054 · NIDCR · STANFORD UNIVERSITY · PI JOHN B SUNWOO · 2020 to 2026
$6.7MStanford Clinician Scientist Training ProgramR25DC020174 · NIDCD · STANFORD UNIVERSITY · PI Alan Gi-Lun Cheng · 2022 to 2026
$1.8MMechanisms of NK cell activation and immune-editing of leukemiaK22CA282364 · NCI · WASHINGTON UNIVERSITY · PI Jennifer Ann Foltz · 2024 to 2026
$581kChimeric Antigen Receptor Modified Natural Killer Cells for the Treatment of Solid TumorsK22CA292567 · NCI · OHIO STATE UNIVERSITY · PI Peter James Chockley · 2025 to 2026
$385kNCI NIH HHS K22 CA282364NCI NIH HHS K22 CA292567NIDCD NIH HHS R25 DC020174NIDCR NIH HHS R35 DE030054
6 · The paper itselfAbstract
Human tissue-resident natural killer (NK) cells (trNK cells), broadly defined by markers of tissue residency, such as CD49a [
Indexed as
Antigens, CDApyraseCytotoxicity, ImmunologicIntegrin alpha1Integrin alpha ChainsKiller Cells, NaturalAnimalsCell Line, TumorFemaleHumansMiceTumor Microenvironmentalpha E integrinsAntigens, CDApyraseIntegrin alpha1Integrin alpha Chains
Identifiers
PMID42090477
PMCPMC13676310
What OpenQuestion holds
Textmetadata
Read underepoch 390